However, the KRAS mutations show uneven prevalence in the pan-cancer studies as KRASG12C and KRASG12V are predominant in non-small cell lung cancer (NCLC) while KRASG12R was more common in pancreatic ductal adenocarcinoma [4, 22, 23]. Here, KRAS is linked to pancreatic ductal adenocarcinoma.